Publications en collaboration avec des chercheurs de Hospital Universitario La Paz (21)

2024

  1. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  2. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer

    Cancers, Vol. 14, Núm. 2

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

  3. miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma

    PloS one, Vol. 15, Núm. 2, pp. e0229075

2019

  1. Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: A meta-analysis of randomized clinical trials

    Oncotarget, Vol. 10, Núm. 35, pp. 3294-3301

  2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

    Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727

  3. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46

2018

  1. Analysis of response rate with ANTI-PD1/PDL-1 monoclonal antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials

    Oncotarget, Vol. 9, Núm. 9, pp. 8706-8715

  2. Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

  3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  4. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer

    Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399

  2. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

2013

  1. The targeted therapy revolution in neuroendocrine tumors: In search of biomarkers for patient selection and response evaluation

    Cancer and Metastasis Reviews, Vol. 32, Núm. 3-4, pp. 465-477

2011

  1. Advances in pancreatic neuroendocrine tumor treatment: [3]

    New England Journal of Medicine